A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study)

StatusActive
Effective start/end date13/10/1612/10/21

Funding

  • Eli Lilly: $119,311.00

Keywords

  • Aging & Alzheimers, Biotechnology & Drug Development